Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial

Johann Schinzel, Lina Schwarzlose, Holger Dietze, Karolina Bartusch, Susanne Weiss, Stephanie Ohlraun, Friedemann Paul, Jan Dörr, Johann Schinzel, Lina Schwarzlose, Holger Dietze, Karolina Bartusch, Susanne Weiss, Stephanie Ohlraun, Friedemann Paul, Jan Dörr

Abstract

Background: Optic neuritis is a frequent manifestation of multiple sclerosis. Visual deficits range from a minor impairment of visual functions through to complete loss of vision. Although many patients recover almost completely, roughly 35% of patients remain visually impaired for years, and therapeutic options for those patients hardly exist. Vision restoration therapy is a software-based visual training program that has been shown to improve visual deficits after pre- and postchiasmatic injury. The aim of this pilot study is to evaluate whether residual visual deficits after past or recent optic neuritis can be reduced by means of vision restoration therapy.

Methods/design: A randomized, controlled, patient- and observer-blinded clinical pilot study (VISION study) was designed to evaluate the efficacy of vision restoration therapy in optic neuritis patients. Eighty patients with a residual visual deficit after optic neuritis (visual acuity ≤0.7 and/or scotoma) will be stratified according to the time of optic neuritis onset (manifestation more than 12 months ago (40 patients, fixed deficit) versus manifestation 2 to 6 months ago (40 patients, recent optic neuritis)), and randomized into vision restoration therapy arm or saccadic training arm (control intervention). Patients will be instructed to complete a computer-based visual training for approximately 30 minutes each day for a period of 6 months. Patients and evaluators remain blinded to the treatment allocation throughout the study. All endpoints will be analyzed and P-values < 0.05 will be considered statistically significant. The primary outcome parameter will be the expansion of the visual field after 3 and 6 months of treatment as determined by static visual field perimetry and high resolution perimetry. Secondary outcome variables will include visual acuity at both low and high contrast, glare contrast sensitivity, visually evoked potentials, optical coherence tomography and other functional tests of the visual system, alertness, health-related quality of life, fatigue, and depression.

Discussion: If vision restoration therapy is shown to improve visual function after optic neuritis, this method might be a first therapeutic option for patients with incomplete recovery from optic neuritis.

Trial registration: NCT01274702.

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517. doi: 10.1016/S0140-6736(08)61620-7.
    1. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung H-P, Hohlfeld R. Multiple Sclerosis Therapy Consensus Group (MSTCG) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255:1449–1463.
    1. Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273–1280. doi: 10.1056/NEJMcp053247.
    1. Pirko I, Blauwet LA, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol. 2004;61:1401–1405. doi: 10.1001/archneur.61.9.1401.
    1. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727–732.
    1. Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004;61:1538–1541.
    1. Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–588. doi: 10.1056/NEJM199202273260901.
    1. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthal. 2004;137:77–83.
    1. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079–1082. e5.
    1. Osborne BJ, Volpe NJ. Optic neuritis and risk of MS: Differential diagnosis and management. Cleve Clin J Med. 2009;76:181–190. doi: 10.3949/ccjm.76a.07268.
    1. Kasten E, Wüst S, Behrens-Baumann W, Sabel BA. Computer-based training for the treatment of partial blindness. Nat Med. 1998;4:1083–1087. doi: 10.1038/2079.
    1. Jung CS, Bruce B, Newman NJ, Biousse V. Visual function in anterior ischemic optic neuropathy: effect of Vision Restoration Therapy - a pilot study. J Neurol Sci. 2008;268:145–149. doi: 10.1016/j.jns.2007.12.001.
    1. Sahraie A, Trevethan CT, MacLeod MJ, Murray AD, Olson JA, Weiskrantz L. Increased sensitivity after repeated stimulation of residual spatial channels in blindsight. Proc Natl Acad Sci U S A. 2006;103:14971. doi: 10.1073/pnas.0607073103.
    1. Schumacher EH, Jacko JA, Primo SA, Main KL, Moloney KP, Kinzel EN, Ginn J. Reorganization of visual processing is related to eccentric viewing in patients with macular degeneration. Restor Neurol Neurosci. 2008;26:391–402.
    1. Jenkins T, Ciccarelli O, Toosy A, Miszkiel K, Wheeler-Kingshott C, Altmann D, Mancini L, Jones S, Plant G, Miller D, Thompson A. Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. Hum Brain Mapp. 2010;31:276–286.
    1. Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N. Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence. Neurology. 2011;76:2103–2111. doi: 10.1212/WNL.0b013e31821f4602.
    1. Korsholm K, Madsen KH, Frederiksen JL, Rowe JB, Lund TE. Cortical neuroplasticity in patients recovering from acute optic neuritis. NeuroImage. 2008;42:836–844. doi: 10.1016/j.neuroimage.2008.05.031.
    1. Korsholm K, Madsen KH, Frederiksen JL, Skimminge A, Lund TE. Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas. Brain. 2007;130:1244–1253. doi: 10.1093/brain/awm045.
    1. Levin N, Orlov T, Dotan S, Zohary E. Normal and abnormal fMRI activation patterns in the visual cortex after recovery from optic neuritis. NeuroImage. 2006;33:1161–1168. doi: 10.1016/j.neuroimage.2006.07.030.
    1. Toosy AT, Hickman SJ, Miszkiel KA, Jones SJ, Plant GT, Altmann DR, Barker GJ, Miller DH, Thompson AJ. Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Ann Neurol. 2005;57:622–633. doi: 10.1002/ana.20448.
    1. Jenkins TM, Toosy AT, Ciccarelli O, Miszkiel KA, Wheeler-Kingshott CA, Henderson AP, Kallis C, Mancini L, Plant GT, Miller DH, Thompson AJ. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol. 2010;67:99–113.
    1. Schulz KF, Altman DG, Moher D. for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251. doi: 10.1371/journal.pmed.1000251.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Friedl-Francesconi H, Binder H. Training in cognitive functions in neurologic rehabilitation of craniocerebral trauma. Z Exp Psychol. 1996;43:1–21.
    1. Hasomed GmbH Homepage: Kompensatorisches Training. .
    1. Bach M. The Freiburg Visual Acuity Test-Variability unchanged by post-hoc reanalysis. Graefes Arch Clin Exp Ophthalmol. 2007;245:965–971. doi: 10.1007/s00417-006-0474-4.
    1. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9:921–932. doi: 10.1016/S1474-4422(10)70168-X.
    1. OCULUS - Products > Vision Test. Apparatus > Ishihara Tests. .
    1. IReST - International Reading Speed Texts: - The Gateway to European Vision Research. .
    1. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–214. doi: 10.1016/S0887-6177(03)00039-8.
    1. Psytest - TAP 2.2: Psytest - TAP 2.2. .
    1. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Invest Ophthalmol Vis Sci. 2000;41:1017–1021.
    1. Bullinger M. Erfassung der gesundheitsbezogenen Lebensqualität mit dem SF-36- Health Survey. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2000;43:190–197. doi: 10.1007/s001030050034.
    1. Gall C, Mueller I, Gudlin J, Lindig A, Schlueter D, Jobke S, Franke GH, Sabel BA. Formatted: English (U.S.) Vision- and health-related quality of life before and after vision restoration training in cerebrally damaged patients. Restor Neurol Neurosci. 2008;26:341–353.
    1. Hamburger Module - HEALTH. .
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123. doi: 10.1001/archneur.1989.00520460115022.
    1. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the Fatigue Severity Scale in a Swiss cohort. Sleep. 2008;31:1601–1607.
    1. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. Psychopathology. 1998;31:160–168. doi: 10.1159/000066239.
    1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg‒Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302. doi: 10.1002/ana.22366.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis. Neurology. 1983;33:1444. doi: 10.1212/WNL.33.11.1444.
    1. Mueller I, Mast H, Sabel BA. Recovery of visual field defects: a large clinical observational study using vision restoration therapy. Restor Neurol Neurosci. 2007;25:563–572.
    1. Horton JC. Disappointing results from Nova Vision’s visual restoration therapy. Br J Ophthalmol. 2005;89:1–2. doi: 10.1136/bjo.2004.058214.
    1. Zihl J. Neuropsychologische Rehabilitation. Grundlagen - Diagnostik. Springer, Behandlungsverfahren; 1988. pp. 105–131.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit